BRPI0922962A2 - inibidores de p38 map quinase - Google Patents
inibidores de p38 map quinaseInfo
- Publication number
- BRPI0922962A2 BRPI0922962A2 BRPI0922962A BRPI0922962A BRPI0922962A2 BR PI0922962 A2 BRPI0922962 A2 BR PI0922962A2 BR PI0922962 A BRPI0922962 A BR PI0922962A BR PI0922962 A BRPI0922962 A BR PI0922962A BR PI0922962 A2 BRPI0922962 A2 BR PI0922962A2
- Authority
- BR
- Brazil
- Prior art keywords
- kinase inhibitors
- map kinase
- map
- inhibitors
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0822609A GB0822609D0 (en) | 2008-12-11 | 2008-12-11 | Novel compounds |
US16659409P | 2009-04-03 | 2009-04-03 | |
GB0912470A GB0912470D0 (en) | 2009-07-17 | 2009-07-17 | Novel compounds |
PCT/GB2009/051703 WO2010067131A1 (en) | 2008-12-11 | 2009-12-11 | P38 map kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0922962A2 true BRPI0922962A2 (pt) | 2019-09-24 |
Family
ID=42242379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0922962A BRPI0922962A2 (pt) | 2008-12-11 | 2009-12-11 | inibidores de p38 map quinase |
Country Status (11)
Country | Link |
---|---|
US (2) | US8299074B2 (pt) |
EP (2) | EP2370429B1 (pt) |
JP (3) | JP5670912B2 (pt) |
KR (2) | KR20110094127A (pt) |
CN (2) | CN102341384B (pt) |
AU (2) | AU2009326148B2 (pt) |
BR (1) | BRPI0922962A2 (pt) |
CA (2) | CA2746357A1 (pt) |
MX (2) | MX2011006220A (pt) |
NZ (1) | NZ593104A (pt) |
WO (2) | WO2010067130A1 (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101665143B1 (ko) | 2007-12-19 | 2016-10-11 | 캔써 리서치 테크놀로지 리미티드 | 피리도[2,3-b]피라진-8 치환 화합물 및 이의 용도 |
CN102256964A (zh) * | 2008-10-02 | 2011-11-23 | 瑞斯比维特有限公司 | p38MAP激酶抑制剂 |
GB0818033D0 (en) * | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
CA2746357A1 (en) * | 2008-12-11 | 2010-06-17 | Respivert Limited | P38 map kinase inhibitors |
GB0905955D0 (en) * | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
GB0921730D0 (en) * | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
GB0921731D0 (en) * | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
CN102906090B (zh) | 2010-02-01 | 2015-06-24 | 癌症研究技术有限公司 | 1-(5-叔丁基-2-苯基-2h-吡唑-3-基)-3-[2-氟-4-(1-甲基-2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶-7-基氧基)-苯基]-脲和相关化合物及它们在治疗中的应用 |
GB201005589D0 (en) * | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
EP2556068B1 (en) | 2010-04-08 | 2019-01-23 | Respivert Limited | P38 map kinase inhibitors |
EP2556067B1 (en) | 2010-04-08 | 2016-02-24 | Respivert Limited | Pyrazolyl ureas as p38 map kinase inhibitors |
GB201009731D0 (en) * | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
GB201010196D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
US8933228B2 (en) | 2010-06-17 | 2015-01-13 | Respivert, Ltd. | Respiratory formulations and compounds for use therein |
GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
JP2014528404A (ja) * | 2011-10-03 | 2014-10-27 | レスピバート・リミテツド | p38MAPキナーゼ阻害剤としての1−ピラゾリル−3−(4−((2−アニリノピリミジン−4−イル)オキシ)ナフタレン−1−イル)尿素 |
DK2788349T3 (en) * | 2011-12-09 | 2017-01-30 | Chiesi Farm Spa | kinase inhibitors |
GB201214750D0 (en) * | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
WO2014033447A2 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
WO2014033446A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
WO2014033449A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
US11052202B2 (en) * | 2012-11-07 | 2021-07-06 | Chiesi Farmaceutici S.P.A. | Drug delivery device for the treatment of patients with respiratory diseases |
WO2014076484A1 (en) | 2012-11-16 | 2014-05-22 | Respivert Limited | Kinase inhibitors |
EP2970190A1 (en) * | 2013-03-14 | 2016-01-20 | Respivert Limited | Kinase inhibitors |
MX363950B (es) * | 2013-04-02 | 2019-04-08 | Topivert Pharma Ltd | Derivados de urea utiles como inhibidores de quinasa. |
EP2981534B1 (en) | 2013-04-02 | 2017-07-19 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
WO2015092423A1 (en) | 2013-12-20 | 2015-06-25 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
CN110522731B (zh) | 2014-02-14 | 2022-08-02 | 瑞斯比维特有限公司 | 作为抗炎化合物的芳族杂环化合物 |
MA40775A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
EP3344258B1 (en) * | 2015-09-21 | 2023-05-10 | Shenzhen Evergreen Therapeutics Co., Ltd. | Treating auto-immune and auto-inflammatory diseases |
AU2017245888B2 (en) | 2016-04-06 | 2021-05-13 | Oxular Acquisitions Limited | Kinase inhibitors |
EP4219489A3 (en) | 2018-05-30 | 2023-11-15 | Washington University | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof |
US20230089368A1 (en) | 2019-07-19 | 2023-03-23 | Anagenesis Biotechnologies S.A.S. | Polyaromatic urea derivatives and their use in the treatment of muscle diseases |
EP4029501A1 (en) | 2021-01-19 | 2022-07-20 | Anagenesis Biotechnologies | Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2308428A1 (en) | 1997-11-03 | 1999-05-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
BR9814361A (pt) | 1997-12-22 | 2001-11-27 | Bayer Ag | Inibição de quinase raf usando uréiasheterocìclicas substituìdas por arila eheteroarila |
US20080300281A1 (en) | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
DK1043995T3 (da) | 1997-12-22 | 2007-03-05 | Bayer Pharmaceuticals Corp | Inhibering af p38 kinaseaktivitet ved anvendelse af aryl- og heteroaryl-substituerede, heterocykliske urinstoffer |
US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
ID26620A (id) * | 1997-12-22 | 2001-01-25 | Bayer Ag | Penghambatan kinase raf yang menggunakan urea-urea heterosiklik yang disubstitusi |
MXPA00006233A (es) * | 1997-12-22 | 2002-09-18 | Bayer Ag | Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas. |
EP1064289A1 (en) | 1998-03-18 | 2001-01-03 | Ariad Pharmaceuticals, Inc. | Heterocyclic signal transduction inhibitors, compositions containing them |
UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
MXPA02000314A (es) | 1999-07-09 | 2004-06-22 | Boehringer Ingelheim Pharma | Proceso novedoso para la sintesis de compuestos de urea substituidos con heteroarilo. |
US6492529B1 (en) * | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
WO2002066442A1 (en) | 2001-02-15 | 2002-08-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents |
JP2004530690A (ja) | 2001-05-16 | 2004-10-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症性薬剤として有用なジアリールウレア誘導体 |
CA2453147A1 (en) | 2001-07-11 | 2003-01-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediated diseases |
WO2003068223A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
EP2324825A1 (en) | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
JP4629978B2 (ja) * | 2002-02-25 | 2011-02-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン媒介疾患の治療に有用な1,4−二置換ベンゾ縮合シクロアルキル尿素化合物 |
IL163737A0 (en) | 2002-04-05 | 2005-12-18 | Boehringer Ingelheim Pharma | Method of treating mucus hypersecretion |
US20060063782A1 (en) * | 2002-07-03 | 2006-03-23 | Murray Christopher W | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors |
US20040110755A1 (en) | 2002-08-13 | 2004-06-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions |
CA2497951A1 (en) | 2002-09-05 | 2004-03-18 | Scios Inc. | Treatment of pain by inhibition of p38 map kinase |
CN1756849A (zh) * | 2002-12-31 | 2006-04-05 | 迪赛孚尔药品研制有限公司 | 蛋白质功能性的调控 |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
EP1599466B1 (en) | 2003-02-28 | 2010-11-24 | Bayer HealthCare LLC | 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders |
CA2517517C (en) | 2003-03-03 | 2012-12-18 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
GB0308511D0 (en) | 2003-04-14 | 2003-05-21 | Astex Technology Ltd | Pharmaceutical compounds |
GB0320244D0 (en) * | 2003-05-06 | 2003-10-01 | Aventis Pharma Inc | Pyrazoles as inhibitors of tumour necrosis factor |
US20070010529A1 (en) | 2003-05-19 | 2007-01-11 | Kanji Takahashi | Nitrogenous heterocyclic compounds and medical use thereof |
WO2005002673A1 (en) * | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Raf kinase inhibitors |
BRPI0413757A (pt) | 2003-08-22 | 2006-10-31 | Boehringer Ingelheim Pharma | métodos para o tratamento de copd e da hipertensão pulmonar |
US20050148605A1 (en) | 2003-11-13 | 2005-07-07 | Ambit Biosciences Corporation | Amide derivatives as ABL modulators |
WO2005115397A2 (en) | 2004-04-29 | 2005-12-08 | Pharmix Corporation | Compositions and treatments for modulating kinase and/or hmg-coa reductase |
ATE517885T1 (de) | 2004-04-30 | 2011-08-15 | Bayer Healthcare Llc | Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs |
WO2005113511A1 (en) | 2004-05-12 | 2005-12-01 | Bristol-Myers Squibb Company | Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
ES2308523T3 (es) | 2004-06-23 | 2008-12-01 | Eli Lilly And Company | Inhibidores de quinasa. |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
US7612200B2 (en) | 2004-12-07 | 2009-11-03 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US20080081833A1 (en) | 2004-12-20 | 2008-04-03 | Astrazeneca Ab | Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors |
EP1836173A4 (en) | 2004-12-23 | 2009-07-08 | Deciphera Pharmaceuticals Llc | ANTI-INFLAMMATORY DRUGS |
EP2942349A1 (en) * | 2004-12-23 | 2015-11-11 | Deciphera Pharmaceuticals, LLC | Enzyme modulators and treatments |
GB0500435D0 (en) * | 2005-01-10 | 2005-02-16 | Novartis Ag | Organic compounds |
DE102005015253A1 (de) | 2005-04-04 | 2006-10-05 | Merck Patent Gmbh | Pyrazolderivate |
CN101203506B (zh) | 2005-06-20 | 2012-02-22 | 泰博特克药品有限公司 | 杂环基氨基烷基取代的苯并咪唑 |
US7700620B2 (en) | 2005-06-27 | 2010-04-20 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
DE102005037499A1 (de) | 2005-08-09 | 2007-02-15 | Merck Patent Gmbh | Pyrazolderivate |
RS52902B (en) | 2005-08-24 | 2014-02-28 | Eisai R & D Management Co. Ltd. | NEW PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) |
WO2007038425A2 (en) | 2005-09-27 | 2007-04-05 | Regents Of The University Of Minnesota | Anti-viral compouinds |
EP1960394A2 (en) | 2005-11-15 | 2008-08-27 | Bayer HealthCare AG | Pyrazolyl urea derivatives useful in the treatment of cancer |
CA2632194C (en) | 2005-11-15 | 2012-01-03 | Array Biopharma Inc. | N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
WO2007064872A2 (en) * | 2005-12-01 | 2007-06-07 | Bayer Healthcare Llc | Urea compounds useful in the treatment of cancer |
ES2378704T3 (es) | 2006-01-27 | 2012-04-17 | Array Biopharma, Inc. | Activadores de la glucocinasa |
JP2009525279A (ja) | 2006-01-30 | 2009-07-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Pparモジュレーターとしてのスピロイミダゾール誘導体 |
WO2007096764A2 (en) | 2006-02-27 | 2007-08-30 | Glenmark Pharmaceuticals S.A. | Bicyclic heteroaryl derivatives as cannabinoid receptor modulators |
JP5238697B2 (ja) | 2006-08-04 | 2013-07-17 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
JP5474065B2 (ja) * | 2008-07-31 | 2014-04-16 | ヒューレット−パッカード デベロップメント カンパニー エル.ピー. | 光信号を増幅、変調及び検出するためのナノワイヤの光学的ブロック・デバイス |
CN102256964A (zh) | 2008-10-02 | 2011-11-23 | 瑞斯比维特有限公司 | p38MAP激酶抑制剂 |
GB0818033D0 (en) * | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
CA2746357A1 (en) * | 2008-12-11 | 2010-06-17 | Respivert Limited | P38 map kinase inhibitors |
GB0905955D0 (en) * | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
-
2009
- 2009-12-11 CA CA2746357A patent/CA2746357A1/en not_active Abandoned
- 2009-12-11 CN CN200980156757.7A patent/CN102341384B/zh not_active Expired - Fee Related
- 2009-12-11 AU AU2009326148A patent/AU2009326148B2/en not_active Ceased
- 2009-12-11 CN CN200980156810.3A patent/CN102333770B/zh not_active Expired - Fee Related
- 2009-12-11 AU AU2009326149A patent/AU2009326149B2/en not_active Ceased
- 2009-12-11 BR BRPI0922962A patent/BRPI0922962A2/pt not_active IP Right Cessation
- 2009-12-11 WO PCT/GB2009/051702 patent/WO2010067130A1/en active Application Filing
- 2009-12-11 WO PCT/GB2009/051703 patent/WO2010067131A1/en active Application Filing
- 2009-12-11 KR KR1020117015734A patent/KR20110094127A/ko not_active Application Discontinuation
- 2009-12-11 MX MX2011006220A patent/MX2011006220A/es active IP Right Grant
- 2009-12-11 US US13/139,010 patent/US8299074B2/en active Active
- 2009-12-11 EP EP09771766.4A patent/EP2370429B1/en active Active
- 2009-12-11 EP EP09768546.5A patent/EP2370428B1/en active Active
- 2009-12-11 US US13/133,998 patent/US8299073B2/en active Active
- 2009-12-11 JP JP2011540219A patent/JP5670912B2/ja active Active
- 2009-12-11 JP JP2011540218A patent/JP2012511563A/ja active Pending
- 2009-12-11 MX MX2011006219A patent/MX2011006219A/es not_active Application Discontinuation
- 2009-12-11 KR KR1020117015760A patent/KR20110094130A/ko not_active Application Discontinuation
- 2009-12-11 NZ NZ593104A patent/NZ593104A/xx not_active IP Right Cessation
- 2009-12-11 CA CA2746354A patent/CA2746354A1/en not_active Abandoned
-
2014
- 2014-09-16 JP JP2014187591A patent/JP5959587B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP5959587B2 (ja) | 2016-08-02 |
EP2370428B1 (en) | 2016-08-10 |
US20110312963A1 (en) | 2011-12-22 |
CN102333770B (zh) | 2015-01-28 |
MX2011006219A (es) | 2011-06-28 |
JP5670912B2 (ja) | 2015-02-18 |
KR20110094127A (ko) | 2011-08-19 |
CA2746354A1 (en) | 2010-06-17 |
JP2015013890A (ja) | 2015-01-22 |
US8299073B2 (en) | 2012-10-30 |
CN102341384A (zh) | 2012-02-01 |
MX2011006220A (es) | 2011-06-28 |
CA2746357A1 (en) | 2010-06-17 |
JP2012511563A (ja) | 2012-05-24 |
AU2009326148B2 (en) | 2014-05-08 |
KR20110094130A (ko) | 2011-08-19 |
US20110294812A1 (en) | 2011-12-01 |
CN102333770A (zh) | 2012-01-25 |
AU2009326149B2 (en) | 2014-01-16 |
WO2010067130A1 (en) | 2010-06-17 |
WO2010067131A1 (en) | 2010-06-17 |
AU2009326149A1 (en) | 2010-06-17 |
JP2012511564A (ja) | 2012-05-24 |
US8299074B2 (en) | 2012-10-30 |
CN102341384B (zh) | 2014-11-12 |
WO2010067130A8 (en) | 2011-04-21 |
EP2370429B1 (en) | 2016-04-20 |
AU2009326148A1 (en) | 2010-06-17 |
EP2370428A1 (en) | 2011-10-05 |
EP2370429A1 (en) | 2011-10-05 |
NZ593104A (en) | 2012-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0922962A2 (pt) | inibidores de p38 map quinase | |
CY2019009I2 (el) | Αναστολεις πρωτεϊνικων κινασων | |
DK2350047T3 (da) | p38-MAP-KINASEINHIBITORER | |
CY2019027I1 (el) | Παραγωγα φωσφορου ως αναστολεις κινασης | |
HK1160129A1 (en) | P38 map kinase inhibitors p38 map | |
DK2247592T3 (da) | Pyrrolopyrazinkinaseinhibitors | |
ATE519763T1 (de) | Pyrrolopyrazin-kinasehemmer | |
BRPI0910668A2 (pt) | inibidores de proteína quinases | |
BRPI0918846A2 (pt) | inibidores de cinase heterocíclica | |
BRPI0920135A2 (pt) | imidazopiridazinacarbonitrilos úteis como inibidores de quinase | |
BRPI0820544A2 (pt) | 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase | |
DK2013175T5 (da) | p38 Map-kinase-inhibitorer | |
BRPI0913879A2 (pt) | fenilpirazinonas como inibidores de quinase | |
BRPI0922937A2 (pt) | inibidores de pirrolopirazinil uréia quinase | |
BRPI0811212A2 (pt) | Inibidores de p70 quinase | |
BRPI0906838A2 (pt) | Pirimidinas como inibidores de quinase | |
BRPI0814797A2 (pt) | Inibidores dna-pk | |
BRPI0922880A2 (pt) | compostos inibidores de quinase | |
BRPI1005327A2 (pt) | derivados de triazolopiridina como inibidores de p38 map quinase | |
BRPI0912475A8 (pt) | compostos como inibidores de quinase | |
BRPI0918564A2 (pt) | inibidores | |
BRPI1013623A2 (pt) | inibidores de ligação de proteína cinase | |
BRPI0716198A2 (pt) | Pirrolo-isoquinolinas como inibidores de cinase | |
DK2170891T3 (da) | Pyrazolopyrimidinon-kinasehæmmere | |
BRPI0719883A2 (pt) | Inibidores de quinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |